DUBLIN–(BUSINESS WIRE)–The “Becker Muscular Dystrophy – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Becker Muscular Dystrophy – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 5 respectively.
Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Topics Covered:
Introduction
Report Coverage
- Becker Muscular Dystrophy – Overview
- Becker Muscular Dystrophy – Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Becker Muscular Dystrophy – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Becker Muscular Dystrophy – Companies Involved in Therapeutics Development
- Armgo Pharma Inc
- Catabasis Pharmaceuticals Inc
- Edgewise Therapeutics
- Epirium Bio Inc
- Italfarmaco SpA
- Milo Biotechnology LLC
- PTC Therapeutics Inc
- ReveraGen BioPharma Inc
- Sarcomed AB
- Stealth BioTherapeutics Corp
- Tivorsan Pharmaceuticals Inc
Becker Muscular Dystrophy – Drug Profiles
- ARM-210 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ataluren – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dextro epicatechin – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- edasalonexent – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EDG-5506 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Becker Muscular Dystrophy – Dormant Projects
- Becker Muscular Dystrophy – Discontinued Products
- Becker Muscular Dystrophy – Product Development Milestones
Featured News & Press Releases
- Aug 12, 2020: Epirium Bio announces commencement of phase 1 clinical trial of EPM-01 in Becker muscular dystrophy
- Apr 14, 2020: Epirium Bio receives FDA orphan-drug designation for EB 002 ((+)-Epicatechin) for the treatment of duchenne and becker muscular dystrophy
- Feb 10, 2016: Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy
- Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference
- Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference
- Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound
- May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound
- Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bu5atk
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900